Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Posted by Brenda Bartman on May 12th, 2026

Savara (NASDAQ:SVRA – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01), FiscalAI reports.

Savara Price Performance

NASDAQ SVRA traded down $0.04 on Tuesday, reaching $5.08. 720,880 shares of the company’s stock traded hands, compared to its average volume of 1,515,326. Savara has a 12 month low of $1.89 and a 12 month high of $7.01. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85. The stock has a 50-day simple moving average of $5.40 and a 200 day simple moving average of $5.46. The stock has a market cap of $1.04 billion, a PE ratio of -9.58 and a beta of 0.28.

Wall Street Analyst Weigh In

SVRA has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating on shares of Savara in a report on Monday, March 16th. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Oppenheimer began coverage on shares of Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. William Blair set a $10.00 price target on shares of Savara in a research note on Monday, March 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $9.13.

Get Our Latest Report on Savara

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. VR Adviser LLC grew its position in Savara by 8.4% during the fourth quarter. VR Adviser LLC now owns 13,740,375 shares of the company’s stock valued at $82,854,000 after acquiring an additional 1,059,332 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Savara by 5.4% during the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock valued at $31,328,000 after purchasing an additional 450,000 shares during the period. RTW Investments LP purchased a new stake in shares of Savara during the fourth quarter valued at approximately $35,893,000. Marshall Wace LLP purchased a new stake in shares of Savara during the fourth quarter valued at approximately $27,496,000. Finally, State Street Corp boosted its stake in shares of Savara by 83.6% during the fourth quarter. State Street Corp now owns 4,333,022 shares of the company’s stock valued at $26,128,000 after purchasing an additional 1,973,164 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Savara Company Profile

(Get Free Report)

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.